SG11202112917PA - Modified viral particles and uses thereof - Google Patents

Modified viral particles and uses thereof

Info

Publication number
SG11202112917PA
SG11202112917PA SG11202112917PA SG11202112917PA SG11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA SG 11202112917P A SG11202112917P A SG 11202112917PA
Authority
SG
Singapore
Prior art keywords
viral particles
modified viral
modified
particles
viral
Prior art date
Application number
SG11202112917PA
Other languages
English (en)
Inventor
Leah Sabin
Christos Kyratsous
Sven Moller-Tank
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202112917PA publication Critical patent/SG11202112917PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202112917PA 2019-05-24 2020-05-22 Modified viral particles and uses thereof SG11202112917PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852791P 2019-05-24 2019-05-24
PCT/US2020/034328 WO2020242984A1 (fr) 2019-05-24 2020-05-22 Particules virales modifiées et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202112917PA true SG11202112917PA (en) 2021-12-30

Family

ID=71094822

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112917PA SG11202112917PA (en) 2019-05-24 2020-05-22 Modified viral particles and uses thereof

Country Status (18)

Country Link
US (1) US20220241430A1 (fr)
EP (1) EP3976631A1 (fr)
JP (1) JP2022533438A (fr)
KR (1) KR20220011664A (fr)
CN (2) CN113874386A (fr)
AR (2) AR118997A1 (fr)
AU (1) AU2020283537A1 (fr)
BR (1) BR112021023692A2 (fr)
CA (1) CA3140386A1 (fr)
CL (2) CL2021003096A1 (fr)
CO (1) CO2021017692A2 (fr)
IL (1) IL288233A (fr)
MA (1) MA56035A (fr)
MX (1) MX2021014338A (fr)
PE (1) PE20212357A1 (fr)
SG (1) SG11202112917PA (fr)
TW (1) TW202110869A (fr)
WO (1) WO2020242984A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020242984A1 (fr) * 2019-05-24 2020-12-03 Regeneron Pharmaceuticals, Inc. Particules virales modifiées et leurs utilisations
WO2022187377A1 (fr) * 2021-03-02 2022-09-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Virus adéno-associés et procédés et matériaux de fabrication et d'utilisation de virus adéno-associés
WO2022232575A1 (fr) * 2021-04-30 2022-11-03 Duke University Compositions comprenant des protéines de capside chimériques de virus adéno-associé et leurs méthodes d'utilisation
AU2022296534A1 (en) * 2021-06-23 2024-01-25 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2023220603A1 (fr) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vecteurs et procédés de production d'anticorps in vivo
WO2023240124A1 (fr) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Particules virales pseudotypées pour le ciblage de cellules exprimant un tcr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510050A (ja) 1995-07-25 1999-09-07 イントロヘーネ ベスローテン フェンノートシャップ 標的遺伝子送達のための方法および手段
WO1998011244A2 (fr) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vecteur de vaa4 et ses utilisations
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
ES2313784T3 (es) 1998-05-28 2009-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Vector aav5 y usos del mismo.
JP4573437B2 (ja) 1998-11-05 2010-11-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス血清型１核酸配列、ベクターおよび同一物を含有する宿主細胞
DK1310571T3 (da) * 2001-11-13 2006-06-19 Univ Pennsylvania Fremgangsmåde til identifikation af ukendte adeno-associerede virussekvenser (AAV-sekvenser) og et kit til fremgangsmåden
EP2158211B1 (fr) 2007-05-31 2016-08-10 Medigene AG Protéine structurale mutée d'un parvovirus
SI2509409T1 (sl) 2009-12-10 2016-12-30 Regeneron Pharmaceuticals, Inc. Miši, ki tvorijo protitelesa težke verige
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
BR112016020783A2 (pt) * 2014-03-10 2017-10-03 Uniqure Ip Bv Vetores de aav adicionalmente melhorados produzidos em células de inseto
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015191508A1 (fr) * 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Capsides chimériques
DK3645553T3 (da) 2017-06-27 2023-05-22 Regeneron Pharma Tropismemodificerede, rekombinante, virale partikler og anvendelser deraf til targeteret indføring af genetisk materiale i humane celler
WO2019006043A1 (fr) 2017-06-27 2019-01-03 Regeneron Pharmaceuticals, Inc. Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines
WO2020242984A1 (fr) * 2019-05-24 2020-12-03 Regeneron Pharmaceuticals, Inc. Particules virales modifiées et leurs utilisations

Also Published As

Publication number Publication date
CL2021003096A1 (es) 2022-09-20
TW202110869A (zh) 2021-03-16
CA3140386A1 (fr) 2020-12-03
MA56035A (fr) 2022-04-06
JP2022533438A (ja) 2022-07-22
WO2020242984A9 (fr) 2021-01-14
IL288233A (en) 2022-01-01
US20220241430A1 (en) 2022-08-04
CO2021017692A2 (es) 2022-01-17
BR112021023692A2 (pt) 2022-01-04
EP3976631A1 (fr) 2022-04-06
WO2020242984A1 (fr) 2020-12-03
AR124119A2 (es) 2023-02-15
CN113874386A (zh) 2021-12-31
MX2021014338A (es) 2022-01-06
AR118997A1 (es) 2021-11-17
CL2023000629A1 (es) 2023-10-20
CN114989267A (zh) 2022-09-02
KR20220011664A (ko) 2022-01-28
AU2020283537A1 (en) 2021-12-16
PE20212357A1 (es) 2021-12-17

Similar Documents

Publication Publication Date Title
IL288233A (en) Modified viral particles and their use
IL290102A (en) Viral vectors of cell lysis and their uses
IL271993A (en) Viral vectors of cell lysis and their uses
HK1254293A1 (zh) 一種重組單純皰疹病毒及其用途
EP4076448A4 (fr) Oxadiazoles fluoroalkylés et leurs utilisations
EP3778882A4 (fr) Composition de virus oncolytique recombinant et utilisation associée
EP3704723C0 (fr) Particules magnétiques améliorées et leurs utilisations
IL289585A (en) DLL3-targeted antibodies and uses thereof
EP3518947C0 (fr) Virus oncolytiques optimisés et utilisations de ces derniers
IL280854A (en) Recombinant myxoma viruses and their use
IL283278A (en) Liver-specific viral promoters and methods of using the same
HK1253377A1 (zh) 可編程的溶瘤病毒疫苗系統及其應用
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
EP4074755A4 (fr) Particules de résine absorbante et absorbant
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL287003A (en) Anti-integrin antibodies and their uses
IL291550A (en) Anti-il-27 antibodies and their uses
IL291546A (en) Antibodies against kir3dl3 and their uses
ZA201908358B (en) Coated particles and their uses
IL291280A (en) Antibodies against cd371 and their uses
ZA202104244B (en) Recombinant viruses and the uses thereof
SG10201905229VA (en) Anti-Dengue Virus Antibodies and Applications Thereof
HK1255099A1 (zh) 重組溶瘤病毒及其用途
EP4041084A4 (fr) Particule nanocomposite et ses utilisations
IL266526A (en) Recombinant virus, preparations containing it and its uses